Inhibition of IL-17A (secukinumab and ixekizumab) alone might increase the risk of uveitis, while simultaneous inhibition of IL-17A and IL-17F (bimekizumab) significantly reduced the risk. The gene discussed is IL17A; the disease is uveitis.